Eloxx Pharma Shares Plummet As Class 1 Cystic Fibrosis Trial Fails

Shares of Eloxx Pharmaceuticals, Inc. (ELOX) are down over 42% at $0.22 in premarket trading session on Thursday, following disappointing results from the company's phase II combination trial of ELX-02 in Class 1 cystic fibrosis patients.

The phase II combination clinical trial was designed to evaluate safety and assess biological activity of of ELX-02 in Class 1 cystic fibrosis patients as monotherapy and in combination with Ivacaftor.

The trial included a 1-week monotherapy period followed by a four-week combination period.

The study did not achieve statistical significance for efficacy endpoints, including changes from baseline in sweat chloride concentration (SCC) and percent forced expiratory volume (FEV1).

ELX-02 was well tolerated with no drug-related serious adverse events observed.

CF patients with a Class 1 nonsense mutation remain highly underserved with no approved disease modifying therapies. An estimated 10-12% of CF patients are Class 1 patients

ELOX has traded in a range of $0.21 to $1.89 in the last 52 weeks. The stock closed Wednesday's trading at $0.38, up 0.24%.

For comments and feedback contact: editorial@rttnews.com

Follow RTT